Publications

2022

Rodino KG, Peaper DR, Kelly BJ, Bushman F, Marques A, Adhikari H, et al. Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1. medRxiv. 2022.
Charpentier M, Spada S, Van Nest SJ, Demaria S. Radiation therapy-induced remodeling of the tumor immune microenvironment. Semin Cancer Biol. 2022;86(Pt 2):737-747.
Fowler FC, Chen B-, Zolnerowich N, Wu W, Pavani R, Paiano J, et al. DNA-PK promotes DNA end resection at DNA double strand breaks in G0 cells. Elife. 2022;11.
Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol (Lausanne). 2022;13:1006101.
Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et al. Germline variants associated with toxicity to immune checkpoint blockade. Nat Med. 2022;28(12):2584-2591.
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, et al. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCI Insight. 2022;7(4).
Han J, Russo G, Stratman S, Psomadakis CE, Rigo R, Owji S, et al. Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine. JAAD Case Rep. 2022;24:101-104.
Einstein EH, Ablyazova F, Rosenberg A, Harshan M, Wahl S, Har-El G, et al. Stimulated Raman histology facilitates accurate diagnosis in neurosurgical patients: a one-to-one noninferiority study. J Neurooncol. 2022;159(2):369-375.
Nascimento J, Mariot C, Vianna DR, Kliemann LM, Chaves PS, Loda M, et al. Fatty acid synthase as a potential new therapeutic target for cervical cancer. An Acad Bras Cienc. 2022;94(2):e20210670.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700